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Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily that are over-expressed in breast
cancer, with context dependent effects on breast cancer pathogenesis. The type III TGF-β receptor (TβRIII)
mediates BMP signaling. While TβRIII expression is lost during breast cancer progression, the role of TβRIII in
regulating BMP signaling in normal mammary epithelium and breast cancer cells has not been examined.
Restoring TβRIII expression in a 4T1 murine syngeneic model of breast cancer suppressed Smad1/5/8
phosphorylation and inhibited the expression of the BMP transcriptional targets, Id1 and Smad6, in vivo.
Similarly, restoring TβRIII expression in human breast cancer cell lines or treatment with sTβRIII inhibited BMP-
induced Smad1/5/8 phosphorylation and BMP-stimulated migration and invasion. In normal mammary epithelial
cells, shRNA-mediated silencing of TβRIII, TβRIII over-expression, or treatment with sTβRIII inhibited BMP-
mediated phosphorylation of Smad1/5/8 and BMP induced migration. Inhibition of TβRIII shedding through
treatment with TAPI-2 or expression of a non-shedding TβRIII mutant rescued TβRIII mediated inhibition of BMP
induced Smad1/5/8 phosphorylation and BMP induced migration and/or invasion in both in normal mammary
epithelial cells and breast cancer cells. Conversely, expression of a TβRIII mutant, which exhibited increased
shedding, significantly reduced BMP-mediated Smad1/5/8 phosphorylation, migration, and invasion. These data
demonstrate that TβRIII regulates BMP-mediated signaling and biological effects, primarily through the ligand
sequestration effects of sTβRIII in normal and cancerous mammary epithelial cells and suggest that the ratio of
membrane bound versus sTβRIII plays an important role in mediating these effects.
Neoplasia (2014) 16, 489–500Abbreviations: BMP, bone morphogenetic protein; TβRIII, type III TGF-β
receptor; sTβRIII, soluble type III TGF-β receptor CM, conditioned media;
TAPI-2, N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L- t-
butyl-alanyl-L-alanine 2-aminoethyl Amide, TNF-α Protease Inhibitor-2; EV,
empty vector; Δshed-TβRIII, non-shedding TβRIII mutant; SS-TβRIII, super
shedding TβRIII mutant
Address all correspondence to: Gerard C. Blobe, Duke University Medical Center,
Department of Medicine, B354 LSRC, Box 91004, Durham NC, 27708.
E-mail: gerard.blobe@duke.edu
1Conflict of interest statement: The authors declare that they have no competing interests.
Received 6 March 2014; Revised 12 May 2014; Accepted 19 May 2014
© 2014 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/). 1476-5586/14
http://dx.doi.org/10.1016/j.neo.2014.05.008Introduction
Bone morphogenetic proteins (BMP), with 20 members, are the largest
subfamily of the TGF-β superfamily [1]. BMPs regulate development,
bone formation and remodeling, proliferation, survival, migration, and
differentiation. BMP signaling occurs upon binding of BMP to the type
I BMP receptor (ALK1, ALK2, ALK3, or ALK6), which then
complexes with and is phosphorylated and activated by one of the
type II BMP receptors (BMPRII, ActRII, or ActRIIB). The activated
type I BMP receptor then phosphorylates the receptor Smad proteins
(Smad1/5/8), which complex with Smad 4, translocate into the nucleus,
and induce transcription of BMP target genes.
Although best characterized for their role in development and bone
morphogenesis, BMPs have important roles in normal mammary gland
development [2–5], and have been reported to have both tumor
suppressor and tumor promoting functions in breast cancer. In human
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levels [6]. In support of a tumor suppressor role, BMP7 has been shown
to reduce both primary tumor growth and bone metastases in a mouse
xenograft model of breast cancer [7] and the inhibition of BMP signaling
through the expression of a dominant negative BMPR2 in a MMTV-
Polyoma middle T mouse model of mammary cancer increased tumor
cell proliferation, lung metastasis, angiogenesis, and induced an altered
reactive tumor stroma [8]. Conversely, in support of a tumor promoting
role, primary human breast cancers, lymph node metastases, and bone
metastases exhibit signs of elevated BMP signaling [9], high BMPR-IB
expression in ER-positive human breast tumors correlates with decreased
survival [10], treatment of human breast cancer cell lines with BMP
promotes cell migration and invasion [6,9,11–14], BMP7 expression in
cell lines and primary breast tumors has been associated with accelerated
bone metastasis in vivo[7,15,16], and expression of dominant negative
BMPRIA in a murine breast cancer xenograft model prevents bone
metastasis and invasion and enhances survival [9].
The type III TGF-β receptor (TβRIII or betaglycan) binds to multiple
BMP family members, including BMP2, 4, 7 andGDF-5, and functions
as a BMP co-receptor, enhancing ligand binding to the BMP type I
receptors, ALK3 and ALK6 [17,18]. Upon complexing with BMP type I
receptors, TβRIII co-localizes and stabilizes ALK3 expression at the cell
surface [19], while mediating the internalization of ALK6 to stimulate
ALK6 signaling in a β-arrestin2 dependent manner [19]. TβRIII is also
able to inhibit both activin and BMP signaling by promoting the binding
of inhibin to its cognate receptors, the activin type II and BMP type II
receptors, as inhibin opposes the action of activin and BMP [20,21]. In
addition, ectodomain shedding of TβRIII produces soluble TβRIII
(sTβRIII), which inhibits TGF-β signaling via ligand sequestration.
However, little is known about the regulation of TβRIII shedding, and
the cleavage site has not been identified [22,23]. While sTβRIII has been
demonstrated to bind BMP, the specific role of sTβRIII in regulating
BMP signaling remains to be defined [18,24,25].
Loss of TβRIII expression occurs early in the development of
human breast cancer, beginning during ductal carcinoma in situ[26].
The restoration of TβRIII expression in breast cancer, inhibits tumor
progression in vivo in part through sTβRIII production, which binds
to and sequesters TGF-β, antagonizing the tumor promoting effects
of TGF-β signaling in late stage tumors [26–31]. Specifically, TβRIII
expression inhibits migration, invasion, angiogenesis, and metastasis
in a murine syngeneic model of breast cancer [26]. Several studies
have demonstrated that treatment with sTβRIII alone inhibits breast
cancer tumor growth, angiogenesis, and reduces metastasis in
xenograft models of breast cancer [27,28,32]. In addition, expression
of TβRIII inhibits BMP-mediated invasion and Smad phosphoryla-
tion in pancreatic cancer [33]. As TβRIII binds to and mediates BMP
signaling, which has been shown to have context dependent roles in
breast cancer progression, here we investigated the role of TβRIII and
sTβRIII in regulating BMP signaling and BMP-mediated biology in
mammary epithelial cells and breast cancer cells, demonstrating that
the ratio of membrane bound versus sTβRIII plays an important role
in mediating BMP signaling and biological effects in mammary
epithelial cells and breast cancer cells.
Material and Methods
Cell Lines
All cell lines were originally obtained from the American Type
Culture Collection (Manassas, VA). Human breast cancer cell linesMDA-MB-231 and MCF-7 were cultured in MEM + 10% FBS,
sodium pyruvate, and non-essential amino acids with the addition of
insulin (10 μg/ml) for the MCF-7 cells. The mouse 4T1 breast cancer
cell line was cultured in DMEM + 10% FBS. The human normal
mammary epithelial cell lines, MCF10A and HMECs were cultured
in F12/DMEM (1:1) + 5% horse serum, 10 μg/ml insulin, 0.5 μg/ml
hydrocortisol, 20 ng/ml EGF, 100 ng/ml cholera toxin and
DMEM +10% FBS, 10 μg/ml insulin, respectively.
MDA-MB-231, MCF-7, and 4T1 stable cell lines, representing a
pool of stable clones, were derived as previously described and
maintained in 250 μg/ml G418 [26,30].
Viral Production and Infection. For lentivirus production, 293FT
cells were transfected with Lipofectamine 2000 (Invitrogen,Grand
Island, NY) at a ratio of 3:1 to DNA, either EV (empty vector),
TβRIII, ΔShed (non-shed), and SS (super-shed) (pSMPUW-Neo
expression vector) (Cell Biolabs, San Diego, CA) and 3 third
generation lentiviral packaging plasmids (AddGene, Cambridge, MA)
in Opti-MEM (Gibco) and media was changed 6 hours post
transfection. Forty-eight hours post infection, media was collected,
spun down to remove cell debris, and filtered through a 0.45 μMpore
membrane. Viral media was aliquoted and stored at −80°C until use.
For lenti-viral infections, viral media was added to cells in complete
growth media at a ratio of either 1:10 or 1:100 in the presence of
polybrene (6 μg/ml). To create stable lentiviral-expressing cell lines,
48 hours post-infection media was changed and complete growth
media containing 2 mg/ml G418 (KSE Scientific, Durham, NC) was
added as a selection agent. Post selection, serial dilutions were used to
create monoclonal cell lines. Following selection, stable lentiviral cell
lines were maintained in complete growth media containing 500 μg/ml
G418. Adenoviral infections were performed as previously described
[34]. All adenoviral infections were performed at a multiplicity of
infection of 50 for all constructs. Cells were treated with 25 μMTAPI-2
(N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-
t-butyl-alanyl-L-alanine, 2-aminoethyl Amide, TNF-α Protease
Inhibitor-2) (EMD Biosciences, San Diego, CA) in fresh media
overnight prior to harvest. Conditioned media (CM): 2 × 10^5 cells
were plated in a 6-well dish and allowed to recover overnight. The
next day cells were incubated in 1ml fresh complete media overnight
and conditioned media was collected, cell debris removed by
centrifugation, and used immediately for signaling experiments or
stored at −80°C until use in ELISA assays.
Western Blotting
2 × 105 cells were plated in six well dishes and allowed to recover.
Cells were serum starved overnight and then treated with varying
doses of BMP2 or 4 for the indicated times. The cells were lysed in
boiling sample buffer and resolved by SDS-PAGE and immuno-
blotted for the proteins of interest. 4T1-Neo and TβRIII tumor
extracts were prepared by homogenization in RIPA buffer plus a
protease inhibitor cocktail (Roche, Indianapolis, IN) and cleared by
centrifugation. Protein concentrations were determined using a BCA
protein quantification assay (Pierce, Rockford, IL). Primary antibod-
ies (p-Smad1/5/8 (#9511), Smad1 (#9743), pSmad2 (#3101),
Smad2 (#5339)) were purchased from Cell Signaling Technology
(Danvers, MA) and a 1:2000 dilution was used for immunoblotting.
Primary TβRIII antibody (#AF-242-PB) was purchased from R&D
systems (Minneapolis, MN USA) and a 1:2000 dilution was used for
immunoblotting. Cells were treated with 60 to 80 ng/ml sTβRIII
recombinant soluble TβRIII (R&D Systems, Minneapolis, MN).
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RNA was extracted from 4T1-Neo and TβRIII mammary tumors
using the RNeasy Lipid Tissue Mini Kit per the manufacturer’s
instructions (Qiagen, Valencia, CA). 1 μg of RNA was reverse
transcribed using the iScript cDNA Synthesis Kit (BioRad Hercules,
CA). Each PCR reaction contained 1 μl of cDNA plus SYBRGreen
Mix (BioRad, Hercules, CA) along with Id1 primers: Id1 F 5′-
GCACTGATCTGCCGTTCAGG-3′ and Id1 R 5′-TGGACGAG
CAGCAGGTGAACG-3′, Smad 6 F 5′-CCACTGGAT CTGTCC-
GATTC-3′ and Smad6 R 5′-AAGTCGAACACCTTGATGGAG-
3′, or GAPDH F 5′-GTCTACA-TGTTCCA-3′ and GAPDH R-5′
AGTGAGTTGTCATATTTCTGTGGT-3′. Id-1 and Smad6 ex-
pression was normalized to GAPDH levels. Student’s t-test was used
to quantitatively assess statistical significance.
Binding and Crosslinking
TGF-β binding and cross linking experiments were performed as
previously described [26,34]. Briefly, 2.5 × 10^4 cells were plated in 6-
well dishes and allowed to recover overnight. The next day, media was
removed and replaced with 1 ml complete growth media. Media was
conditioned for 24 hours before being removed and centrifuged to
remove cell debris prior to binding and crosslinking. Both cells and
conditioned media were incubated with 125I-TGF-β1 (Perkin Elmer,
Waltham, MA), at 100 pM and 25 pM, respectively, in the presence of
BSA and protease inhibitors for 3 hours at 4°C. After incubation, ligand
was chemically crosslinked using 0.5 mg/ml disuccinimidyl suberate
and quenched with 1M glycine. Cells were lysed with RIPA buffer
supplemented with protease inhibitors, and ligand-receptor complexes
were immunoprecipitated with a polyclonal antibody against the
extracellular domain of TβRIII (R&D Systems, Minneapolis, MN).
The resulting complexes were separated via SDS-PAGE. Images were
acquired with phosphorimaging and were analyzed using ImageJ
software (National Institutes of Health (NIH)).
Migration/Invasion Transwell Assays
To assess invasion or migration, 7.5 × 104 cells were seeded in serum
free media in the upper chamber of a Matrigel invasion transwell (BD
Biosciences, San Jose CA) or a fibronectin coated transwell filter, coated
both at the top and bottom with 30 μg/mL fibronectin (Calbiochem,
La Jolla, CA) for HMECs or 50 μg/ml for MDA-MB-231 cells. Cells
were untreated, treated with 20 nM BMP2, 20 nM BMP4 (R&D
Systems, Minneapolis, MN) and/or 25 μMTAPI-2, as well as 60 to 80
ng/ml soluble recombinant TβRIII (R&D Systems,Minneapolis, MN)
where indicated and were allowed to migrate for 24 h at 37°C toward
the lower chamber containing media plus 10% FBS. Cells on the upper
surface of the filter were removed and the cells that migrated to the
underside of the filter were fixed and stained using the 3 Step Stain Set
(Richard-Allan Scientific, Kalamazoo, MI). Each assay was performed
in duplicate, and each experiment was conducted at least 3 times with 3
random fields from a 20× magnification analyzed for each membrane.
Data analysis was performed using NIH ImageJ software (http://rsb.
info.nih.gov/ij/). Student’s t test was used to quantitatively assess
statistical significance.sRIII ELISA
Conditioned media (CM): 2 × 10^5 cells were plated in a 6 well dish
and allowed to recover overnight. The next day cells were incubated in
1ml fresh complete media with FBS overnight and conditioned media
was collected, cell debris removed by centrifugation stored at −80°Cuntil use in ELISA assays. Capture antibody (R&D Systems, #AF-242-
PB, Minneapolis, MN) was immobilized onto an E1A/R1A plate
(#3590 Corning, Union City, California) overnight. After washing,
100 μl conditioned media was loaded onto the plate and incubated at
room temperature for 2 hours. Then detection antibody (# BAF-242,
R&D Systems, Minneapolis, MN) was applied and incubated for 2 h,
Strepavidin-HRP (# DY998, R&D Systems, Minneapolis, MN) added
and incubated for 30 minutes. Finally Fast OPD substrate (# P9187,
Sigma Aldrich, St. Louis, MO) was added, 3MHCl was applied to stop
the reaction 30 minutes later, and optical absorbance at 490 nm was
recorded immediately.
Results
TβRIII inhibits BMP-mediated signaling in breast cancer cells
As TβRIII mediates BMP signaling and regulates breast cancer
progression, [18,26,35,36], we investigated the role of TβRIII in
regulating BMP signaling in breast cancer. In several human and
murine models of breast cancer, including the human breast cancer
cell lines, MDA-MB-231 and MCF-7, and the mouse breast cancer
cell line, 4T1, all of which express low levels of TβRIII, BMP2 or
BMP4 stimulated time and dose dependent increases in Smad1/5/8
phosphorylation (Figure 1A–C; Suppl. Figure S1A). This BMP-
mediated Smad1/5/8 phosphorylation was ALK3/ALK6 depen-
dent, as treatment with the ALK3/6 inhibitor, dorsomorphin,
potently suppressed BMP's effects (Suppl. Figure S1C). Compared
to Neo control cells, stably expressing TβRIII in MDA-MB-231,
MCF-7 and 4T1 cells (Suppl. Figure S1E) [26,35,37,38],
decreased BMP2 and BMP4 induced Smad1/5/8 phosphorylation
(Figure 1A–C; Suppl. Figure S1A). In addition, as BMPs have
been recently shown to induce phosphorylation of Smad2/3
preferentially in cancer cells, including these breast cancer cells
[39], we demonstrated that expression of TβRIII in MDA-MB-231
cells also inhibited BMP2 induced Smad2 phosphorylation
(Suppl. Figure S1B).TβRIII inhibits BMP-mediated signaling in an in vivo model
of breast cancer
To examine the role of TβRIII in regulating BMP signaling in an
in vivo breast cancer context, we examined whether expression of
TβRIII in a 4T1murine syngeneic model of breast cancer alters BMP
signaling. Expression of TβRIII in this system has been previously
demonstrated to suppress tumor progression through inhibition of
migration, invasion, angiogenesis, and metastasis, due in part to
sTβRIII-mediated inhibition of TGF-β/pSmad2 signaling [26,35].
Primary 4T1-Neo and 4T1-TβRIII breast tumors [26] were
examined for levels of Smad1/5/8 phosphorylation and alterations
in the downstream BMP transcriptional targets, Idl and Smad6.
Western blot analysis of pSmad1/5/8 protein levels in primary
tumors demonstrated that, in comparison to Neo tumors, 4T1-
TβRIII tumors exhibited a significant decrease in Smad1/5/8
phosphorylation (Figure 1D). In addition, relative to 4T1-Neo
tumors, 4T1-TβRIII primary tumors had a significant decrease in
mRNA levels of two BMP transcriptional targets, Id1 and Smad6,
supporting a role for TβRIII in suppressing BMP-mediated
transcriptional events in vivo (Figure 1E). These data demonstrate
that expression of TβRIII in an in vivo model of breast cancer
suppresses BMP signaling at both the level of Smad phosphorylation
and downstream transcriptional regulation.
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Figure 1. TβRIII inhibits BMP-mediated signaling in breast cancer cells and a 4T1 orthotopic breast cancer model. (A) Western blot
analysis of pSmad1/5/8 signaling in MDA-MB-231-Neo and TβRIII stable cells serum starved overnight and then treated with BMP2 at the
indicated dosages and times. (B) Western blot analysis of pSmad1/5/8 signaling in MCF7-Neo and TβRIII stable cells serum starved
overnight and then treated with BMP2 at the indicated dosages and times. (C) Western blot analysis of pSmad1/5/8 signaling in 4T1-Neo
and TβRIII stable cells serum starved overnight and then treated with BMP4 at the indicated dosages and times. (D) Western blot analysis
of pSmad1/5/8 signaling in primary tumors (n = 3, Neo and TβRIII) from a 4T1-Neo and TβRIII orthotopic xenograft model of breast cancer
[26]. (E) QRT-PCR analysis of BMP transcriptional targets Id1 (n = 5) and Smad6 (n = 4) in 4T1-Neo and TβRIII primary breast tumors [26].
The fold change in mRNA is shown normalized to GAPDH control. Total Smad1 and β-Actin levels are shown as loading controls for
westerns. All experiments were independently performed at least 3 times and representative data are shown. Id1 P = .03; t-test. Smad6
P = .05; t test.
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epithelial cell lines
As TβRIII regulated BMP signaling in breast cancer cells, we
investigated the role of TβRIII in regulating BMP signaling in the
cellular origin of breast cancers, normal mammary epithelial cells.
The normal human mammary epithelial cell lines, MCF10A and
HMEC, both express TβRIII and are responsive to BMP4 treatment,
as demonstrated by BMP4-mediated dose and time dependent
Smad1/5/8 phosphorylation (Figure 2A). This BMP-mediated
Smad1/5/8 phosphorylation was ALK3/ALK6 dependent, as
treatment with dorsomorphin potently suppressed BMP’s effects in
HMEC and MCF10A cells (Suppl. Figure S1D). As normalmammary epithelial cells expressed TβRIII, we utilized shRNA-
mediated knockdown of TβRIII expression to assess the role of
TβRIII in BMP signaling. In both HMEC and MCF10A cells,
shRNA-mediated knockdown of TβRIII expression attenuated
BMP-mediated Smad1/5/8 phosphorylation, demonstrating that
TβRIII has an important role in mediating BMP signaling in normal
mammary epithelial cells (Figure 2B and D).
As increasing TβRIII expression in breast cancer cell lines had a
similar effect to decreasing TβRIII expression in normal mammary
epithelial cells, we investigated the effects of increasing TβRIII
expression in normal mammary epithelial cells. Surprisingly,
increasing expression of TβRIII also inhibited BMP-mediated
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Figure 2. TβRIII inhibits BMP signaling in normal mammary epithelial cells. (A) Western blot analysis of pSmad1/5/8 signaling in HMECs
and MCF10A cells serum starved overnight and treated with BMP4 at the indicated dosages and times (5 nM BMP4). (B) Western blot
analysis of pSmad1/5/8 signaling in NTC (non-targeting control) or shRNA-TβRIII adenovirally infected HMECs. Cells were serum starved
overnight and treated with BMP2 at the indicated dosages (10 minute treatment) and times (5nM BMP2). (C) Western blot analysis of
pSmad1/5/8 signaling in GFP or TβRIII-GFP adenovirally infected HMECs. Cells were serum starved overnight and then treated with BMP2
at the indicated dosages and times. (D) Western blot analysis of pSmad1/5/8 signaling in NTC (non-targeting control) or shRNA TβRIII
adenovirally infectedMCF10A cells serum starved overnight and treated with BMP4 at the indicated dosages. (E) Western blot analysis of
pSmad1/5/8 signaling in GFP or TβRIII-GFP adenovirally infected MCF10A cells serum starved overnight and treated with 10 nM BMP2.
Total Smad1 and β-actin levels are shown as loading controls for westerns. All experiments were independently performed at least
3 times and representative data are shown.
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cell line (Figure 2C and E). To investigate whether this inhibition
could be attributed to increased soluble TβRIII (sTβRIII)
production, we assessed both cell surface TβRIII and sTβRIII
expression while increasing TβRIII expression. Consistent with
previous studies, binding and crosslinking demonstrated that over-
expression of TβRIII in HMECs increased expression of both
membrane bound TβRIII and sTβRIII (Suppl. Figure S2A), with a
preference for increased sTβRIII relative to membrane bound
TβRIII. sTβRIII ELISA assays also demonstrated increased levels of
sTβRIII in conditioned media (CM) from HMECs which over-
express TβRIII and a reciprocal decrease in levels of sTβRIII inmedia from cells in which endogenous TβRIII expression has been
silenced by shRNA (Suppl. Figure S2B).
sTβRIII inhibits BMP signaling in mammary epithelial and
breast cancer cells
sTβRIII is able to bind BMP2 [18] and has been shown to inhibit
TGF-β signaling in breast cancer cells, suggesting that TβRIII may
inhibit BMP signaling in the context of mammary epithelial cells
through the production of sTβRIII [26,35]. Consistent with this
hypothesis, treatment of HMECs and MCF10A cells with either
recombinant sTβRIII or CM from MDA-MB-231-TβRIII cells
inhibited BMP-mediated induction of pSmad1/5/8 (Figure 3A, B,
Figure 3. sTβRIII inhibits BMP signaling inmammary epithelial cells. (A and B)Western blot analysis of pSmad1/5/8 signaling in HMEC and
MCF10A cells serum starved overnight and pretreated with sTβRIII (60 ng/ml) or conditioned (CM) fromMDA-MB-231- TβRIII cells prior to
BMP2 (B2) and 4 (B4) treatment. (C) Western blot analysis of pSmad1/5/8 signaling in MDA-MB-231-Neo and TβRIII stable cells serum
starved and pre-treated with recombinant sTβRIII (60 ng/ml) overnight and subsequently treated with BMP4 at the indicated dosages.
(D) Western blot analysis of pSmad1/5/8 signaling in MDA-MB-231-Neo and TβRIII stable cells serum starved and treated with CM from
MDA-MB-231-TβRIII cells and subsequently treated with BMP2 and 4 at the indicated dosages. (E) Western blot analysis of pSmad1/5/8
signaling in HMECs serum starved overnight and treated with pre-treated with recombinant sTβRIII at the indicated dosages. Cells were
treated with 10nMBMP2 for 10minutes. (F) Western blot analysis of pSmad1/5/8 signaling inMDA-MB-231 cells serum starved overnight
and treated with pre-treated with recombinant sTβRIII at the indicated dosages. Cells were treated with 10nM BMP2 for 10 minutes.
(G) Western blot analysis of pSmad1/5/8 in HMECs adenovirally infected with GFP or TβRIII-GFP serum starved overnight and pretreated
with 25 μM TAPI-2 prior to treatment with 10 nM BMP2 for 10 minutes. (H) Western blot analysis of pSmad1/5/8 signaling in MDA-MB-
231-Neo and TβRIII cells serum starved and pretreated overnight with 25 μM TAPI-2 prior to treatment with 10nM BMP2 for 10 minutes.
Total Smad1 and β-actin levels are shown as loading controls for westerns. All experiments were independently performed at least
3 times and representative data are shown.
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Figure 4. TβRIII mediates BMP induced migration and invasion in mammary epithelial cells. (A) GFP, TβRIII-GFP, NTC (non-targeting
control), or shTβRIII adenovirally infected HMECs were plated in a fibronectin transwell migration assay in serum free conditions on a
fibronectin coated transwell with and without BMP2 and/or sTβRIII (60 ng/ml) treatment for 24 hours. Data was normalized to GFP UT or
NTC UT respectively and fold change ± SEM is shown. *P≤ .05; t test (B) GFP or TβRIII-GFP adenovirally infected HMECswere plated in a
fibronectin transwell migration assay in serum free conditions on a fibronectin coated transwell with and without BMP2 and/or 25 μM
TAPI-2 treatment for 24 hours. Data was normalized to GFP UT and fold change ± SEM is shown. *P ≤ .05; t test. (C) MDA-MB-231-Neo
and TβRIII cells were plated in a fibronectin transwell migration assay in serum free conditions on a fibronectin coated transwell with and
without BMP2, BMP4, and/or sTβRIII (60 ng/ml) treatment for 24 hours. Data was normalized to Neo UT and fold change ± SEM is shown.
*P ≤ 0.05; t test. (D) MDA-MB-231-Neo and TβRIII cells were plated in a matrigel transwell invasion assay in serum free conditions on a
matrigel coated transwell with and without BMP2, BMP4, treatment and/or CM (conditioned media) fromMDA-MB-231-TβRIII cells for 24
hours. Data was normalized to Neo UT and fold change ± SEM is shown. *P≤ .05; t test. All experiments were independently performed
at least 3 times and representative data are shown.
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recombinant sTβRIII or with CM from MDA-MB-231-TβRIII
cells (Figure 3C and D) inhibited BMP2 and BMP4 mediated
Smad1/5/8 phosphorylation. The sTβRIII mediated suppression of
BMP2 induced pSmad1/5/8 in HMECs and MDA-MB-231 cells
occurred in a dose dependent manner (Figure 3E and F). Further,
inhibition of TβRIII shedding by treatment with TAPI-2, an MMP
and TACE inhibitor [40], (Suppl. Figure S3A, B), rescued TβRIII
mediated suppression of BMP2 induced Smad1/5/8 phosphoryla-
tion in HMECs and in MDA-MB-231 cells (Figure 3G and H).
These data demonstrate that TβRIII inhibits BMP signaling in
both normal and cancerous mammary epithelial cell lines, at least in
part via sTβRIII-mediated BMP sequestration.TβRIII mediates BMP induced migration and invasion in
normal and cancerous mammary epithelial cells
TβRIII regulates cell motility and invasion in a variety of cell types
[26,33,34,41,42] and BMP induces migration and invasion in breast
cancer cell lines as well as regulating metastasis in vivo [9,13].
Accordingly, we investigated the role of TβRIII in BMP induced
migration through fibronectin coated transwells and invasion through
Matrigel coated transwells. HMECs demonstrated a modest yet
significant increase in migration in response to BMP2, which was
abrogated by treatment with recombinant sTβRIII, increasing TβRIII
expression or by shRNA-mediated silencing of TβRIII expression
(Figure 4A, Suppl. Figure S2 C), corresponding to the effects of
sTβRIII, and altered TβRIII expression on BMP signaling in
Figure 5. TβRIII shedding mutants alter BMP mediated signaling, migration, and invasion in mammary epithelial cells. (A) Western blot
analysis of pSmad1/5/8 in HMECs transfected with vector control, TβRIII, shed-TβRIII, or SS-TβRIII. Transfected HMECs were serum
starved overnight prior to BMP2 treatment. (B) Vector control, TβRIII, shed-TβRIII, or SS-TβRIII transfected HMECs were plated in a
fibronectin transwell migration assay in serum free conditions on a fibronectin coated transwell with and without BMP2 treatment for 24
hours. Data was normalized to vector UT and fold change ± SEM is shown. *P ≤ .05; t test. (C) Western blot analysis of pSmad1/5/8
signaling in MDA-MB-231 monoclonal lenti-stable cell lines. Cells were serum starved overnight and treated for 10 minutes with BMP2.
(D and E) Western blot analysis of pSmad1/5/8 signaling in MDA-MB-231-EV, TβRIII, shed-TβRIII, or SS-TβRIII MDA-MB-231 monoclonal
stable cell lines. Media was changed to 1mL overnight and cells were treated the next day with BMP2 at the indicated dosages and times.
(F) MDA-MB-231-EV, TβRIII, shed-TβRIII, or SS-TβRIII monoclonal stable cell cells were plated in a matrigel transwell invasion with serum
free CM (24 hour conditioning) from corresponding cells on a matrigel coated transwell with and without BMP2 treatment assay for 24
hours. Data was normalized to EV UT as well as normalized for proliferation and fold change ± SEM is shown. *P ≤ .05; t test. (G) MDA-
MB-231-EV, TβRIII, shed-TβRIII, or SS-TβRIII monoclonal stable cells were plated in a fibronectin transwell migration assay with serum
free CM from corresponding cells on a matrigel coated transwell with and without BMP2 treatment. Data was normalized to EV UT as well
as normalized for proliferation and fold change ± SEM is shown. *P ≤ .05; t test. β-Actin levels are shown as loading controls for
westerns. All experiments were independently performed at least 3 times and representative data are shown.
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TAPI-2 to inhibit TβRIII shedding significantly enhanced basal
migration of GFP and TβRIII-HMECs and blocked the ability of
increased TβRIII expression to inhibit BMP-mediated migration
(Figure 4B, Suppl. Figure S3C). These studies demonstrate that
TβRIII regulates BMP-mediated migration in normal mammary
epithelial cells, suggesting that the balance between membrane bound
and sTβRIII is important in regulating BMP signaling and migration
in this context.
MDA-MB-231-Neo cells were also responsive to BMP2 and
BMP4 treatment, with BMP2 and BMP4 both enhancing migration
and invasion (Figure 4C and D; Suppl. Figure S4). Similar to
HMECs, stable over-expression of TβRIII in MDA-MB-231 cells
inhibited BMP2 and BMP4 induced migration and invasion
(Figure 4C and D; Suppl. Figure S4). Further, treatment of MDA-
MB-231-Neo cells with recombinant sTβRIII or CM from MDA-
MB-231-TβRIII cells significantly inhibited BMP-induced migration
and invasion (Figure 4C and D; Suppl. Figure S4A, B), suggesting
that the increased levels of sTβRIII in the MDA-MB-231-TβRIII
cells contributes to the reduction in BMP-mediated migration and
invasion. Taken together, these data demonstrate that TβRIII can
regulate BMP-mediated migration and invasion in both normal and
cancerous mammary epithelial cells.
TβRIII shedding mutants demonstrate altered BMP mediated
signaling, migration and invasion in mammary epithelial cells
To further address the effect of sTβRIII on BMP signaling in
mammary epithelial cells, we utilized two TβRIII mutants that
exhibit alterations in TβRIII shedding, Δshed-TβRIII, which reduces
TβRIII shedding by ~90%, and SS-TβRIII, which increases TβRIII
shedding by ~3- to 4-fold (J.L.E., C.E.G., submitted for publica-
tion). Expression of Δshed-TβRIII failed to inhibit BMP induced
Smad1/5/8 phosphorylation in HMECs (Figure 5A). Conversely,
expression of SS-TβRIII reduced BMP-mediated Smad1/5/8 phos-
phorylation (Figure 5A). In addition, while expression of wild type
TβRIII significantly inhibited BMP induced migration in HMECs,
expression of Δshed-TβRIII did not inhibit BMP-induced migration
in HMECs (Figure 5B, Suppl. Figure S3D). Conversely, expression
of SS-TβRIII significantly reduced BMP-induced migration
(Figure 5B, Suppl. Figure S3D).
Monoclonal lentiviral stable MDA-MB-231 EV (empty vector),
TβRIII, Δshed-TβRIII, and SS-TβRIII cells lines were created to
examine the effects of the ratio of membrane bound versus sTβRIII
on BMP signaling and biology in breast cancer cells (J.L.E., C.E.G.
submitted for publication). Expression of wild type TβRIII inhibited
BMP induced pSmad1/5/8 as previously shown (Figures 1 and 5C).
In contrast, in comparison to wild type TβRIII, expression of Δshed-
TβRIII failed to inhibit BMP induced pSmad1/5/8, while SS-TβRIII
further suppressed BMP induced pSmad1/5/8 (Figure 5C). These
effects are further supported by time course and dose response studies
of BMP2 treatment in the MDA-MB-231 lenti-stable cell lines
(Figure 5D and E). Further, while expression of wild type TβRIII
inhibited BMP induced migration and invasion in MDA-MB-231
lentiviral stable cells, expression of Δshed-TβRIII did not inhibit
BMP induced migration and invasion and was not significantly
reduced compared to EV (Figure 5F and G, Suppl. Figure S4C, D).
In addition, compared to untreated EV, basal migration and invasion
were significantly increased in Δshed-TβRIII (Figure 5F and G,
Suppl. Figure S4C, D). Conversely, expression of SS-TβRIIIsignificantly reduced BMP-mediated migration and invasion
(Figure 5F and G, Suppl. Figure S4C, D). These migration and
invasion data were normalized to a thymidine incorporation assay to
account for any potential differences in proliferation. These data
demonstrate that the ratio of membrane bound and soluble TβRIII is
an important regulator of BMP signaling and BMP-mediated biology
in mammary epithelial cells and cancer cells.
Discussion
TβRIII exerts dual effects on BMP signaling in normal mammary
epithelial cells; cell surface, membrane bound endogenous TβRIII
potentiates BMP signaling (Figure 2), while sTβRIII inhibits
signaling, presumably via sequestration of ligand (Figure 3) [18,19].
Although BMP has been previously shown to bind to sTβRIII, the
effects of sTβRIII on BMP signaling and BMP-mediated biology had
not been previously established [18]. Here we demonstrate that the
ratio of membrane bound versus sTβRIII has an important role in
regulating BMP signaling and BMP-mediated biological effects in
mammary epithelial cells and breast cancer cells, with sTβRIII
mediated suppression of BMP signaling inhibiting breast cancer cell
migration and invasion.
While initially a paradox, the ability of increasing or decreasing
TβRIII expression to inhibit BMP-mediated signaling, migration,
and invasion support a role for the balance of cell surface TβRIII and
soluble TβRIII in regulating BMP responsiveness in mammary
epithelial cells. In normal mammary epithelial cells, increasing TβRIII
expression, which enhances levels of sTβRIII, or treatment with
sTβRIII, suppresses BMP signaling and BMP-mediated migration,
while the loss of cell surface TβRIII via shRNA-mediated silencing
also inhibits BMP signaling and migration, supporting an important
role for membrane bound TβRIII in regulating and facilitating BMP
signaling (Figures 2 and 3). Similarly, restoring TβRIII expression,
which enhances production of sTβRIII, or recombinant sTβRIII
treatment in the human MDA-MB-231, MCF-7, and mouse 4T1
breast cancer cell lines inhibited BMP induced Smad1/5/8
phosphorylation, migration, and invasion (Figure 1). In addition,
TβRIII expression suppresses Smad1/5/8 phosphorylation and
inhibits the expression of the BMP transcriptional targets Id1 and
Smad6 in an in vivo 4T1 syngeneic model of breast cancer,
supporting a role for TβRIII in mediating BMP signaling in vivo
(Figure 1). Further supporting an important role for the ratio of
membrane bound and sTβRIII in regulating BMP signaling,
treatment of mammary epithelial cells with TAPI-2, an inhibitor of
TβRIII shedding, or expression of Δshed-TβRIII, a non-shedding
mutant, rescued TβRIII induced inhibition of BMP-mediated
Smad1/5/8 phosphorylation, migration, and invasion, while a mutant
TβRIII with increased shedding, SS-TβRIII, further suppressed BMP
signaling and BMP-mediated biology (Figure 5).
As we have shown that sTβRIII plays an important role in
inhibition of BMP signaling, dysregulation of TβRIII shedding may
also contribute to the dual role of BMP signaling. Loss of soluble
TβRIII production with the maintenance of membrane bound
TβRIII may potentiate BMP signaling, contributing to tumor
progression. Indeed, we observe cell surface expression of endogenous
TβRIII with little to no sTβRIII production in the MDA-MB-231
cells, a metastatic and invasive breast cancer cell line, in which BMP
mediated migration and invasion can be inhibited by treatment with
recombinant sTβRIII [26]. Although sTβRIII levels correlate with
cell surface levels of TβRIII, little is known about mechanisms
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has not been identified [22,23]. Previous studies suggest that MT-
MMPs regulate TβRIII shedding, which is supported here by the
ability of TAPI-2, a TACE and MMP inhibitor, to suppress TβRIII
shedding (Figure 3) [40]. sTβRIII has been detected in the
extracellular matrix and in serum [22,23,43] and may also have
locoregional effects on the tumor microenvironment, as well as
systemic effects, both of which may contribute to its capability to
suppress metastasis. Further work to understand the regulation of
TβRIII shedding and identify the cleavage site may allow TβRIII
shedding and production of subsequent sTβRIII levels to be
modulated to inhibit BMP signaling and subsequent effects on
breast cancer progression.
The loss of TβRIII that occurs during breast cancer progression
may help explain the dual role of BMP signaling in breast cancer, as
we have demonstrated that TβRIII and sTβRIII regulate BMP
signaling [26]. Early in breast cancer tumorigenesis, maintenance of
TβRIII expression and baseline production of sTβRIII may inhibit
BMP mediated migration and invasion within the tumor context.
Supporting this, we observed a decrease in BMP signaling in primary
4T1-TβRIII tumors and decreased BMP-mediated migration and
invasion in TβRIII expressing cells (Figures 1 and 4). In contrast, loss
of TβRIII expression during cancer progression would result in loss of
sTβRIII expression as well, which would increase BMP-mediated
signaling and increase BMP-promoted migration and invasion. As
loss of TβRIII expression occurs early in breast cancer progression, the
subsequent deregulation of both BMP and TGF-β signaling may
contribute to tumor progression and tumor promoting functions of
these ligands [26].
BMP plays an important role in mediating breast cancer
progression and bone metastasis [9,15,44], suggesting that the ability
of sTβRIII to inhibit breast cancer metastasis may occur through the
inhibition of BMP signaling as well as TGF-β signaling. As there is
significant crosstalk between TGF-β and BMP, inhibition of both
pathways may be required to fully suppress TGF-β superfamily
mediated tumor progression. Supporting this, both BMP and TGF-β
transcriptional pathways are active in metastatic bone lesions of breast
cancer and phosphorylation of both Smad2/3 and Smad1/5/8 has
been observed in primary human and murine xenograft breast cancers
and bone metastases [9,35]. Interestingly, the ability of TβRIII to
inhibit tumor suppression appears to be dependent at least in part on
the production of sTβRIII, which sequesters and inhibits both TGF-β
and BMP signaling. Expression of TβRIII in a murine model of breast
cancer has been shown to have effects on metastasis, angiogenesis,
apoptosis, [26] and the immune response [45] through inhibition of
TGF-β mediated signaling, and the data here support that these
effects are observed for BMP signaling in vivo as well. Indeed, we
observe decreased Smad1/5/8 phosphorylation and suppression of
BMP transcriptional targets Id1 and Smad6 in an in vivo 4T1-TβRIII
syngeneic model of breast cancer, where TβRIII expression decreased
metastasis, invasion, and angiogenesis (Figure 1) [26]. As sTβRIII is
secreted into the extracellular matrix and BMP signaling regulates the
tumor microenvironment [8,46], sTβRIII may have effects on the
tumor microenvironment through the suppression of both TGF-β
and BMP signaling pathways. The regulation of TβRIII expression
and subsequent effects on down-stream signaling may be cell type
specific and ligand specific. Glucocorticoids, specifically dexameth-
asone, potentiate TGF-β signaling via the Acvrl1/Smad1/5/8
signaling axis and repress the Tgfbr1/Smad2/3 axis through the up-regulation of TβRIII expression in NIH3T3 cells, primary lung
fibroblasts, smooth muscle cells and endothelial cells [47]. In
addition, BMPs induce phosphorylation of Smad2/3 preferentially
in cancer cells, including breast cancer cells [39], and we have
demonstrated here that the expression of TβRIII in MDA-MB-231
cells also inhibited BMP2 induced Smad2 phosphorylation.
sTβRIII is capable of inhibiting both BMP and TGF-β signaling,
therefore it provides a unique opportunity to dually target both
signaling pathways as a therapeutic agent. Loss of TβRIII expression
occurs via epigenetic silencing in multiple human tumor types,
suggesting that treatment with histone deacetylase inhibitors or DNA
methylation inhibitors could be utilized to restore TβRIII expres-
sion [31]. The expression of membrane bound TβRIII correlates with
the production of sTβRIII, suggesting that the restoration of TβRIII
cell surface expression in human tumors could have therapeutic
benefits, as has been demonstrated in multiple murine models of
cancer [22,23,26,27,29,30,32,35,48]. Indeed, receptor trap mole-
cules, partially based on TβRIII are currently being developed [49].
As well as therapeutic implications, TβRIII expression may have
prognostic value as a biomarker, as loss of TβRIII expression increases
with clinical stage and correlates with metastatic disease in multiple
tumor types, including breast cancer [26].
Conclusions
In conclusion, we demonstrate that TβRIII regulates BMP signaling
in normal and cancerous mammary epithelial cells, regulating cell
migration and invasion, in part through the sTβRIII-mediated
inhibition of BMP signaling. These data suggest that the ratio of
membrane bound versus sTβRIII plays an important role in
regulating BMP signaling and biological effects in mammary
epithelial cells and breast cancer cells.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.neo.2014.05.008.
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